Rafferty Asset Management, LLC - BIOCRYST PHARMACEUTICALS INC ownership

BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 241 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.25 and the average weighting 0.3%.

Quarter-by-quarter ownership
Rafferty Asset Management, LLC ownership history of BIOCRYST PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$5,719,847
-16.7%
807,888
-17.1%
0.03%
-12.8%
Q2 2023$6,863,740
+0.3%
974,963
+18.8%
0.04%
-15.2%
Q1 2023$6,843,145
-22.4%
820,521
+6.8%
0.05%
-37.8%
Q4 2022$8,817,478
+35.8%
768,073
+49.1%
0.07%
+7.2%
Q3 2022$6,492,000
+58.4%
515,228
+33.0%
0.07%
+81.6%
Q2 2022$4,098,000
-24.0%
387,327
+16.8%
0.04%
+18.8%
Q1 2022$5,394,000
-14.0%
331,713
-26.7%
0.03%
-3.0%
Q4 2021$6,269,000
+112.8%
452,637
+120.8%
0.03%
+65.0%
Q3 2021$2,946,000
+19.4%
204,998
+31.3%
0.02%
+25.0%
Q2 2021$2,468,000
-7.9%
156,107
-40.8%
0.02%
-11.1%
Q1 2021$2,681,000
+220.3%
263,584
+134.6%
0.02%
+125.0%
Q4 2020$837,000
-53.7%
112,351
-78.7%
0.01%
-63.6%
Q3 2020$1,808,000
+70.4%
526,302
+136.4%
0.02%
+46.7%
Q2 2020$1,061,000
+3020.6%
222,617
+1194.3%
0.02%
+1400.0%
Q1 2020$34,000
-93.3%
17,200
-88.2%
0.00%
-87.5%
Q4 2019$504,000
-35.1%
146,084
-46.2%
0.01%
-33.3%
Q3 2019$777,000
-46.1%
271,376
-28.7%
0.01%
-52.0%
Q2 2019$1,442,000
+68.7%
380,494
+262.2%
0.02%
+78.6%
Q1 2019$855,000105,0400.01%
Other shareholders
BIOCRYST PHARMACEUTICALS INC shareholders Q1 2023
NameSharesValueWeighting ↓
VHCP Management II, LLC 6,071,142$38,430,00018.43%
RTW INVESTMENTS, LP 4,078,895$25,819,0009.72%
VHCP Management, LLC 1,155,104$7,312,0007.86%
RA Capital Management 2,989,795$18,925,0002.68%
DLD Asset Management, LP 1,258,700$7,967,0002.61%
Avoro Capital Advisors LLC 1,631,502$10,327,0002.09%
Ghost Tree Capital, LLC 1,150,000$7,280,0001.75%
GREAT POINT PARTNERS LLC 725,000$4,589,0000.94%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 3,237,734$20,495,0000.84%
Baker Brothers Advisors 10,963,944$69,402,0000.68%
View complete list of BIOCRYST PHARMACEUTICALS INC shareholders